Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, CSL commits to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
In honor of Rare Disease Day, we share the voices of patients and caregivers on how others can support them as they manage co…
On a trip supporting the World Federation of Hemophilia’s Humanitarian Aid Program, CSL’s Senior Director of Global Policy an…
In honor of Alpha-1 Awareness Month, we look back at the 2025 Escape to the Cape Bike Trek.
Learn how to participate in the Living Rare Study, which aims to document the burden of rare diseases over time.
Did you know? Some scientists believe the Vikings may have passed down the inherited rare condition Alpha-1 Antitrypsin Defic…
The first and only sports competition for kids and teens living with bleeding disorders returns to Nevada next year. Here’s h…
Bringing transformative, single-dose treatments to patients means working through new questions. CSL Behring’s Diego Sacrista…
CSL Vifor supported the initiative, which invited patients to choose a visual identity designed to raise awareness and unite …
Upwards of 300,000 European patients depend on plasma-derived medicinal products (PDMPs). Policies under consideration could …
Antti Kourula, CSL Behring’s Vice President of Commercial Development for Hematology, recently traveled to the Central Asian …
In honor of Rare Disease Day, we asked patients and caregivers how others can support them as they manage complex medical con…
Kids in a rare disease research trial deserve extra care. That’s why CSL decided to be the first ever to provide “Clinical Co…
Americas
Asia Pacific
Middle East
Europe
